

## New ruthenium(II) complexes bearing 8-hydroxyquinolines derivatives and their biological applications

**Jerica M. Montilla-Suarez<sup>1</sup>, Ana C. Assis<sup>2</sup>, Rodrigo D. Soares<sup>2</sup>, Marcos Palmeira<sup>1</sup>, Alzir A. Batista<sup>1</sup>, and Rodrigo S. Correa<sup>3</sup>**

<sup>1</sup>Department of Chemistry, Federal University of São Carlos, CEP 13565-905, São Carlos, SP, Brazil

<sup>2</sup>Biological Sciences Research Center/NUPEB, UFOP, CEP 35400-000, Ouro Preto, MG, Brazil

<sup>3</sup>Department of Chemistry, Federal University of Ouro Preto, CEP 35400-000, Ouro Preto, MG, Brazil

E-mail: [jerica@estudante.ufscar.br](mailto:jerica@estudante.ufscar.br)

**Thematic Area:** Biological Inorganic Chemistry

**Keywords:** Ruthenium(II), hydroxyquinoline ligands, Leishmania

Ruthenium(II)-based complexes have been investigated as promising metallodrug candidates. An interesting strategy can be the synergic effect of using an active molecule as a ligand to improve the pharmacological response. De Sousa *et al.* demonstrated the antileishmanial activity of clioquinol (CLQ) against two relevant species of *Leishmania* [1]. These studies represent an opportunity for developing new metal complexes with ruthenium [2]. The synthesis, characterization, and evaluation of biological activities of two novel ruthenium(II) complexes with CLQ and 8-hydroxyquinoline (8HQ), are presented here. The complexes with formula  $\text{Ru}(\text{CLQ})(\text{PPh}_3)_2(\text{bipy})\text{PF}_6$  (**complex I**) and  $\text{Ru}(\text{8HQ})(\text{PPh}_3)_2(\text{bipy})\text{PF}_6$  (**complex II**) have molar conductivity of 71 and 95  $\text{Scm}^2\text{mol}^{-1}$ , in methanol, attributed to a 1:1 electrolyte. The FT-IR spectra have bands at 1550 ( $\nu\text{C}=\text{N}$ ), 1490 ( $\nu\text{C}=\text{C}_{\text{ring}}$ ), 1090 ( $\nu\text{C}-\text{P}$ ), and 833 ( $\nu\text{P}-\text{F}$ )  $\text{cm}^{-1}$  representing the major functional groups in the complexes. The complexes exhibited bands at 257 nm, 362 nm, and 470 nm related to intraligand  $\pi \rightarrow \pi^*$  and MLTC transitions. Furthermore, elemental analysis, cyclic voltammetry, and NMR spectroscopy were used to characterized the complexes. The Ru(II) metal center present Ru(II)/Ru(III) oxidation potentials around 858 mV for **complex I** and 713, 842 mV for **complex II**. The  $^{31}\text{P}\{^1\text{H}\}$  NMR spectra present one singlet signal around 25 ppm, referring to the equivalent P atoms on the complexes. The structures of the complexes were confirmed as a distorted octahedral structure (with bond angles different from 90°) by single-crystal X-ray diffraction. The complexes have the P atoms of the  $\text{PPh}_3$  in a *trans* position and the two N atoms of the bipy in a *trans* position to the N-O atoms of the CLQ and 8HQ ligands. Spectrophotometric titrations, DNA viscosity measurements, and electrophoresis experiments were performed to understand the interaction of the complexes with DNA. The intrinsic binding constants  $K_b$  are around  $10^4$ - $10^5 \text{ M}^{-1}$ . These suggests a moderate interaction with CT-DNA as non-covalent, including intercalation, hydrogen bonding, or hydrophobic interactions. Cytotoxicity studies show  $\text{IC}_{50}$  values on *Leishmania infantum* of 35.56 and 3.289  $\mu\text{M}$  for **complex I** and **II**, respectively. **Complex II** is more cytotoxic on *Leishmania infantum* than the free ligand 8HQ ( $\text{IC}_{50} > 200 \mu\text{M}$ ). This result is in agreement with data reported in the literature for similar complexes with structure  $[\text{Ru}(\text{8HQs})(\text{dppf})(\text{NN})]\text{PF}_6$  [3]. In this study, the  $\text{IC}_{50}$  values in *Leishmania infantum* are between 3.0–4.8  $\mu\text{M}$ . In this sense, our **complex II** becomes a promising candidate for drug development studies.

**Acknowledgments:** CAPES, CNPq, FAPEMIG, FAPESP, UFOP and UFSCar

### References

- [1] De Sousa G. *et al.*, *Basic & Clinical Pharmacology & Toxicology*, **123**, 236-246 (2018).
- [2] Wang Z. *et al.*, *J of Inor Biochem*, (2023).
- [3] Rivas F. *et al.*, *J of Inor Biochem*, **237**, 112016 (2022).